SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+35.45%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.57B
AUM Growth
+$1.57B
(+40%)
Cap. Flow
+$103M
Cap. Flow
% of AUM
6.58%
Top 10 Holdings %
Top 10 Hldgs %
73.25%
Holding
67
New
8
Increased
18
Reduced
9
Closed
10
Top Buys
| 1 |
Sanofi
SNY
|
$37.3M |
| 2 |
Gilead Sciences
GILD
|
$29.8M |
| 3 |
AstraZeneca
AZN
|
$21.1M |
| 4 |
Merck
MRK
|
$19.2M |
| 5 |
Intuitive Surgical
ISRG
|
$18.1M |
Top Sells
| 1 |
Novo Nordisk
NVO
|
$30.5M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$21.1M |
| 3 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$15.8M |
| 4 |
Regenxbio
RGNX
|
$14.9M |
| 5 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$14.6M |
Sector Composition
| 1 | Healthcare | 99.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $466M | 27.13% |
2,073,124
| – | – |
|
|
CINC
2
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $200M | 11.61% |
6,079,949
+506,000
| +9% | +$16.6M |
|
3
Natera
NTRA
$23.2B
| $136M | 7.91% |
3,102,960
| – | – |
|
4
Vera Therapeutics
VERA
$1.44B
| $67.8M | 3.94% |
3,181,442
| – | – |
|
|
JBIO
5
Jade Biosciences, Inc. Common Stock
JBIO
$249M
| $62.3M | 3.63% |
3,758,686
| – | – |
|
6
Ascendis Pharma
ASND
$12.1B
| $51.6M | 3% |
499,824
| – | – |
|
|
7
Merck
MRK
$214B
| $50.2M | 2.92% |
583,468
+222,507
| +62% | +$19.2M |
|
|
8
Sanofi
SNY
$121B
| $48.1M | 2.8% |
1,264,546
+982,346
| +348% | +$37.3M |
|
|
9
AstraZeneca
AZN
$249B
| $38.5M | 2.24% |
701,878
+385,518
| +122% | +$21.1M |
|
10
Y-mAbs Therapeutics
YMAB
$389M
| $31.6M | 1.84% |
2,194,278
| – | – |
|
11
United Therapeutics
UTHR
$18.3B
| $30.9M | 1.8% |
147,564
+41,185
| +39% | +$8.62M |
|
|
12
Gilead Sciences
GILD
$140B
| $29.8M | 1.73% |
+482,400
| New | +$29.8M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.3B
| $25M | 1.45% |
294,750
-6,855
| -2% | -$581K |
|
|
CTIC
14
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $21M | 1.22% |
3,612,376
+907,866
| +34% | +$5.28M |
|
|
RETA
15
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $20.6M | 1.2% |
818,376
+34,525
| +4% | +$868K |
|
|
16
Intuitive Surgical
ISRG
$168B
| $18.1M | 1.05% |
+96,300
| New | +$18.1M |
|
17
iRhythm Technologies
IRTC
$5.5B
| $17.6M | 1.02% |
140,095
-1,996
| -1% | -$250K |
|
18
DexCom
DXCM
$29.1B
| $16.6M | 0.97% |
205,948
+16,856
| +9% | +$1.36M |
|
19
Sarepta Therapeutics
SRPT
$1.77B
| $15.6M | 0.91% |
141,440
+10,195
| +8% | +$1.13M |
|
20
Cytokinetics
CYTK
$5.94B
| $15.5M | 0.9% |
320,722
-58
| -0% | -$2.81K |
|
|
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $14.7M | 0.86% |
820,665
+167,618
| +26% | +$3.01M |
|
22
Eli Lilly
LLY
$659B
| $14.7M | 0.86% |
+45,500
| New | +$14.7M |
|
23
Zentalis Pharmaceuticals
ZNTL
$124M
| $12.6M | 0.74% |
583,357
+254,960
| +78% | +$5.52M |
|
24
Syndax Pharmaceuticals
SNDX
$1.39B
| $12.6M | 0.73% |
525,002
+111,574
| +27% | +$2.68M |
|
25
Edwards Lifesciences
EW
$48B
| $12.2M | 0.71% |
+147,200
| New | +$12.2M |
|